Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
Fungal plasma membrane proton pumps as promising new antifungal targets.
Crit Rev Microbiol. 1994;20(3):209-23. Unique Identifier : AIDSLINE GENBANK/X65738 Monk BC; Perlin DS; Department of Oral Biology and Oral Pathology, Faculty of; Dentistry, University of Otago, Dunedin, New Zealand.
Abstract:
Fungi are widely dispersed in nature and frequently appear as pathogens in the animal and plant kingdoms. The incidence of opportunistic fungal infections in humans has increased due to the human immunodeficiency virus and the application of modern medical approaches that subvert natural protective barriers to infection. Also, fungal blights continue to threaten crops worldwide. As a result, new antifungal agents are needed to address these critical problems. Existing antifungals can be used to effectively treat most cases of topical infection caused by the opportunistic pathogen Candida albicans, which is the principal agent of nosocomially acquired fungal infections. However, life-threatening, disseminated Candida infections are treated with more modest success. Existing antifungals can be toxic or ineffective because of natural resistance or even induced resistance. This limited efficacy largely reflects the restricted range of cellular targets considered during the development of current antifungals. The advancement of highly selective fungicidal reagents requires the recognition of new essential cellular targets. The fungal plasma-membrane proton pump is a high-abundance essential enzyme with a number of well-understood molecular properties that should facilitate the development of new antifungals. The proton pump is important for intracellular pH regulation and the maintenance of electrochemical proton gradients needed for nutrient uptake. It is a member of the P-type class of ion-transport enzymes, which are present in nearly all external cellular membranes. Typical P-type enzymes such as the Na+,K(+)-ATPase and H+,K(+)-ATPase are well established as specific targets for surface-active cardiac glycosides and anti-ulcer therapeutics. The development of new classes of selective antifungals targeted to the proton pump will require exploitation of the well-characterized genetic, kinetic, topological, regulatory, and drug-interaction features of the fungal enzyme that discriminate it from related host P-type enzymes. New antifungal drugs of this type should be relevant to the control of fungal pathogens of medical and agricultural importance and may be applicable to the control of intracellular parasites that also depend on closely related proton pumps for survival.
Keywords: Adenosinetriphosphatase/*DRUG EFFECTS Amino Acid Sequence Antifungal Agents/*PHARMACOLOGY Cell Membrane/DRUG EFFECTS H(+)-K(+)-Exchanging ATPase/DRUG EFFECTS H(+)-Transporting ATP Synthase/DRUG EFFECTS Molecular Sequence Data Na(+)-K(+)-Exchanging ATPase/DRUG EFFECTS Proton Pump/*DRUG EFFECTS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC 950430
M9541045
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
